DEVIL'S CLAW

OTHER NAME(S):

Devils Claw, Devil's Claw Root, Garra del Diablo, Grapple Plant, Griffe du Diable, Harpagophyti Radix, Harpagophytum, Harpagophytum procumbens, Harpagophytum zeyheri, Racine de Griffe du Diable, Racine de Windhoek, Teufelskrallenwurzel, Uncaria procumbens, Wood Spider.<br/><br/>

Overview

Overview Information

Devil's claw is an herb. The botanical name, Harpagophytum, means "hook plant" in Greek. This plant gets its name from the appearance of its fruit, which is covered with hooks meant to attach onto animals in order to spread the seeds. The roots and tubers of the plant are used to make medicine.

Devil's claw is used for "hardening of the arteries" (atherosclerosis), arthritis, gout, muscle pain (myalgia), back pain, fibromyalgia, tendonitis, chest pain, gastrointestinal (GI) upset or heart burn, fever, and migraine headache. It is also used for difficulties in childbirth, menstrual problems, allergic reactions, loss of appetite, and kidney and bladder disease.

Some people apply devil's claw to the skin for injuries and other skin conditions.

How does it work?

Devil's claw contains chemicals that might decrease inflammation and swelling and resulting pain.

Uses

Uses & Effectiveness?

Possibly Effective for

  • Back pain. Taking devil's claw by mouth seems to reduce low-back pain. Devil's claw seems to work about as well as some non-steroidal anti-inflammatory drugs (NSAIDs).
  • Osteoarthritis. Taking devil's claw alone or along with nonsteroidal anti-inflammatory drugs (NSAIDs) seems to help decrease osteoarthritis-related pain. Some evidence suggests that devil's claw works about as well as diacerhein (a slow-acting drug for osteoarthritis that is not available in the U.S.) for improving osteoarthritis pain in the hip and knee after 16 weeks of treatment. Some people taking devil's claw seem to be able to lower the dose of NSAIDs they need for pain relief.

Insufficient Evidence for

  • Rheumatoid arthritis (RA). Early research suggests that taking devil's claw extract by mouth might not improve RA.
  • Gout.
  • High cholesterol.
  • Loss of appetite.
  • Muscle pain.
  • Migraine headache.
  • Skin injuries and conditions.
  • Upset stomach.
  • Other conditions.
More evidence is needed to rate devil's claw for these uses.

Side Effects

Side Effects & Safety

Devil's claw is POSSIBLY SAFE for most adults when taken by mouth in appropriate doses for up to a year. The most common side effect is diarrhea. About 8% of the people participating in one research study developed diarrhea. Other possible side effects include nausea, vomiting, stomach pain, headaches, ringing in the ears, loss of appetite, and loss of taste. It can also cause allergic skin reactions, menstrual problems, and changes in blood pressure. But these events are uncommon.

Not enough is known about the safety of using devil's claw long-term or applying it to the skin.

Special Precautions & Warnings:

Pregnancy and breast-feeding: Devil's claw is POSSIBLY UNSAFE. It might harm the developing fetus. Avoid use in pregnancy. It is also best to avoid using devil's claw while breast-feeding. Not enough is known yet about its safety during breast-feeding.

Heart problems, high blood pressure, low blood pressure: Since devil's claw can affect heart rate, heartbeat, and blood pressure, it might harm people with disorders of the heart and circulatory system. If you have one of these conditions, talk with your healthcare provider before starting devil's claw.

Diabetes: Devil's claw might lower blood sugar levels. Using it along with medications that lower blood sugar might cause blood sugar to drop too low. Monitor blood glucose levels closely. Your healthcare provider might need to adjust your dose of diabetes medications.

Gallstones: Devil's claw might increase bile production. This could be a problem for people with gallstones. Avoid using devil's claw.

Peptic ulcer disease (PUD): Since devil's claw might increase the production of stomach acids This might harm people with stomach ulcers. Avoid using devil's claw.

Interactions

Interactions?

Moderate Interaction

Be cautious with this combination

!
  • Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) interacts with DEVIL'S CLAW

    Some medications are changed and broken down by the liver.<br /><br /> Devil's claw might decrease how quickly the liver breaks down some medications. Taking devil's claw along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking devil's claw talk to your healthcare provider if you take any medications that are changed by the liver.<br /><br /> Some medications that are changed by the liver include omeprazole (Prilosec), lansoprazole (Prevacid), and pantoprazole (Protonix); diazepam (Valium); carisoprodol (Soma); nelfinavir (Viracept); and others.

  • Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with DEVIL'S CLAW

    Some medications are changed and broken down by the liver.<br /><br /> Devil's claw might decrease how quickly the liver breaks down some medications. Taking devil's claw along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking devil's claw talk to your healthcare provider if you take any medications that are changed by the liver.<br /><br /> Some medications that are changed by the liver include diclofenac (Cataflam, Voltaren), ibuprofen (Motrin), meloxicam (Mobic), and piroxicam (Feldene); celecoxib (Celebrex); amitriptyline (Elavil); warfarin (Coumadin); glipizide (Glucotrol); losartan (Cozaar); and others.

  • Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with DEVIL'S CLAW

    Some medications are changed and broken down by the liver.<br /><br /> Devil's claw might decrease how quickly the liver breaks down some medications. Taking devil's claw along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking devil's claw, talk to your healthcare provider if you are taking any medications that are changed by the liver.<br /><br /> Some medications changed by the liver include lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), triazolam (Halcion), and many others.

  • Warfarin (Coumadin) interacts with DEVIL'S CLAW

    Warfarin (Coumadin) is used to slow blood clotting. Devil's claw might increase the effects of warfarin (Coumadin) and increase the chances of bruising and bleeding. Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.

Minor Interaction

Be watchful with this combination

!
  • Medications that decrease stomach acid (H2-Blockers) interacts with DEVIL'S CLAW

    Devil's claw might increase stomach acid. By increasing stomach acid, devil's claw might decrease the effectiveness of some medications that decrease stomach acid, called H2-Blockers.<br /><br /> Some medications that decrease stomach acid include cimetidine (Tagamet), ranitidine (Zantac), nizatidine (Axid), and famotidine (Pepcid).

  • Medications that decrease stomach acid (Proton pump inhibitors) interacts with DEVIL'S CLAW

    Devil's claw might increase stomach acid. By increasing stomach acid, devil's claw might decrease the effectiveness of medications that are used to decrease stomach acid, called proton pump inhibitors.<br /><br /> Some medications that decrease stomach acid include omeprazole (Prilosec), lansoprazole (Prevacid), rabeprazole (Aciphex), pantoprazole (Protonix), and esomeprazole (Nexium).

Dosing

Dosing

The following doses have been studied in scientific research:

BY MOUTH:

  • For osteoarthritis: 2-2.6 grams of devil's claw extract have been taken in up to three divided doses daily for up to 4 months. A specific combination product providing 600 mg of devil's claw, 400 mg of turmeric, and 300 mg of bromelain has been taken 2-3 three times daily for up to 2 months.
  • For back pain: 0.6-2.4 grams of devil's claw extract has been taken daily, usually in divided doses, for up to 1 year.

View References

REFERENCES:

  • Evans, G., Luddington, R., and Baglin, T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br.J.Haematol. 2001;115(4):998-1001. View abstract.
  • Fetrow, C. W., Overlock, T., and Leff, L. Antagonism of warfarin-induced hypoprothrombinemia with use of low-dose subcutaneous vitamin K1. J.Clin.Pharmacol. 1997;37(8):751-757. View abstract.
  • Fondevila, C. G., Grosso, S. H., Santarelli, M. T., and Pinto, M. D. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study. Blood Coagul.Fibrinolysis 2001;12(1):9-16. View abstract.
  • Gijsbers, B. L., Jie, K. S., and Vermeer, C. Effect of food composition on vitamin K absorption in human volunteers. Br.J.Nutr. 1996;76(2):223-229. View abstract.
  • Glover, J. J. and Morrill, G. B. Conservative treatment of overanticoagulated patients. Chest 1995;108(4):987-990. View abstract.
  • Goldstein, J. N., Thomas, S. H., Frontiero, V., Joseph, A., Engel, C., Snider, R., Smith, E. E., Greenberg, S. M., and Rosand, J. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006;37(1):151-155. View abstract.
  • Greer, F. R., Marshall, S. P., Severson, R. R., Smith, D. A., Shearer, M. J., Pace, D. G., and Joubert, P. H. A new mixed micellar preparation for oral vitamin K prophylaxis: randomised controlled comparison with an intramuscular formulation in breast fed infants. Arch.Dis.Child 1998;79(4):300-305. View abstract.
  • Habu, D., Shiomi, S., Tamori, A., Takeda, T., Tanaka, T., Kubo, S., and Nishiguchi, S. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 7-21-2004;292(3):358-361. View abstract.
  • Hathaway, W. E., Isarangkura, P. B., Mahasandana, C., Jacobson, L., Pintadit, P., Pung-Amritt, P., and Green, G. M. Comparison of oral and parenteral vitamin K prophylaxis for prevention of late hemorrhagic disease of the newborn. J.Pediatr. 1991;119(3):461-464. View abstract.
  • Hogenbirk, K., Peters, M., Bouman, P., Sturk, A., and Buller, H. A. The effect of formula versus breast feeding and exogenous vitamin K1 supplementation on circulating levels of vitamin K1 and vitamin K-dependent clotting factors in newborns. Eur.J.Pediatr. 1993;152(1):72-74. View abstract.
  • Hosoi, T. [Treatment of primary osteoporosis with vitamin K2]. Clin.Calcium 2007;17(11):1727-1730. View abstract.
  • Hotta, N., Ayada, M., Sato, K., Ishikawa, T., Okumura, A., Matsumoto, E., Ohashi, T., and Kakumu, S. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007;54(79):2073-2077. View abstract.
  • Hung, A., Singh, S., and Tait, R. C. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br.J.Haematol. 2000;109(3):537-539. View abstract.
  • Hylek, E. M., Chang, Y. C., Skates, S. J., Hughes, R. A., and Singer, D. E. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch.Intern.Med. 6-12-2000;160(11):1612-1617. View abstract.
  • Inoue, T., Fujita, T., Kishimoto, H., Makino, T., Nakamura, T., Nakamura, T., Sato, T., and Yamazaki, K. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J.Bone Miner.Metab 2009;27(1):66-75. View abstract.
  • Ishida, Y. [Vitamin K2]. Clin.Calcium 2008;18(10):1476-1482. View abstract.
  • Ishida, Y. and Kawai, S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am.J.Med. 10-15-2004;117(8):549-555. View abstract.
  • Iwamoto, J. [Anti-fracture efficacy of vitamin K]. Clin.Calcium 2009;19(12):1805-1814. View abstract.
  • Iwamoto, J., Matsumoto, H., and Takeda, T. Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials. Clin.Drug Investig. 2009;29(7):471-479. View abstract.
  • Iwamoto, J., Sato, Y., Takeda, T., and Matsumoto, H. High-dose vitamin K supplementation reduces fracture incidence in postmenopausal women: a review of the literature. Nutr.Res. 2009;29(4):221-228. View abstract.
  • Iwamoto, J., Takeda, T., and Ichimura, S. Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. J.Orthop.Sci. 2000;5(6):546-551. View abstract.
  • Iwamoto, J., Takeda, T., and Ichimura, S. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J.Orthop.Sci. 2001;6(6):487-492. View abstract.
  • Iwamoto, J., Takeda, T., and Sato, Y. Role of vitamin K2 in the treatment of postmenopausal osteoporosis. Curr.Drug Saf 2006;1(1):87-97. View abstract.
  • Jie, K. S., Bots, M. L., Vermeer, C., Witteman, J. C., and Grobbee, D. E. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. Atherosclerosis 1995;116(1):117-123. View abstract.
  • Jones, K. S., Bluck, L. J., Wang, L. Y., and Coward, W. A. A stable isotope method for the simultaneous measurement of vitamin K1 (phylloquinone) kinetics and absorption. Eur.J.Clin.Nutr. 2008;62(11):1273-1281. View abstract.
  • Jorgensen, F. S., Felding, P., Vinther, S., and Andersen, G. E. Vitamin K to neonates. Peroral versus intramuscular administration. Acta Paediatr.Scand. 1991;80(3):304-307. View abstract.
  • Kalkwarf, H. J., Khoury, J. C., Bean, J., and Elliot, J. G. Vitamin K, bone turnover, and bone mass in girls. Am.J.Clin.Nutr. 2004;80(4):1075-1080. View abstract.
  • Kazzi, N. J., Ilagan, N. B., Liang, K. C., Kazzi, G. M., Poland, R. L., Grietsell, L. A., Fujii, Y., and Brans, Y. W. Maternal administration of vitamin K does not improve the coagulation profile of preterm infants. Pediatrics 1989;84(6):1045-1050. View abstract.
  • Kim, H. S., Park, J. W., Jang, J. S., Kim, H. J., Shin, W. G., Kim, K. H., Lee, J. H., Kim, H. Y., and Jang, M. K. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J.Clin.Gastroenterol. 2009;43(5):482-488. View abstract.
  • Klebanoff, M. A., Read, J. S., Mills, J. L., and Shiono, P. H. The risk of childhood cancer after neonatal exposure to vitamin K. N.Engl.J.Med. 9-23-1993;329(13):905-908. View abstract.
  • Knapen, M. H., Schurgers, L. J., and Vermeer, C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos.Int. 2007;18(7):963-972. View abstract.
  • Kumar, D., Greer, F. R., Super, D. M., Suttie, J. W., and Moore, J. J. Vitamin K status of premature infants: implications for current recommendations. Pediatrics 2001;108(5):1117-1122. View abstract.
  • Liu, J., Wang, Q., Gao, F., He, J. W., and Zhao, J. H. Maternal antenatal administration of vitamin K1 results in increasing the activities of vitamin K-dependent coagulation factors in umbilical blood and in decreasing the incidence rate of periventricular-intraventricular hemorrhage in premature infants. J.Perinat.Med. 2006;34(2):173-176. View abstract.
  • Liu, J., Wang, Q., Zhao, J. H., Chen, Y. H., and Qin, G. L. The combined antenatal corticosteroids and vitamin K therapy for preventing periventricular-intraventricular hemorrhage in premature newborns less than 35 weeks gestation. J.Trop.Pediatr. 2006;52(5):355-359. View abstract.
  • Lousberg, T. R., Witt, D. M., Beall, D. G., Carter, B. L., and Malone, D. C. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch.Intern.Med. 3-9-1998;158(5):528-534. View abstract.
  • Lubetsky, A., Hoffman, R., Zimlichman, R., Eldor, A., Zvi, J., Kostenko, V., and Brenner, B. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb.Res. 2004;113(6):371-378. View abstract.
  • Lubetsky, A., Yonath, H., Olchovsky, D., Loebstein, R., Halkin, H., and Ezra, D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch.Intern.Med. 11-10-2003;163(20):2469-2473. View abstract.
  • Maas, A. H., van der Schouw, Y. T., Beijerinck, D., Deurenberg, J. J., Mali, W. P., Grobbee, D. E., and van der Graaf, Y. Vitamin K intake and calcifications in breast arteries. Maturitas 3-20-2007;56(3):273-279. View abstract.
  • Macdonald, H. M., McGuigan, F. E., Lanham-New, S. A., Fraser, W. D., Ralston, S. H., and Reid, D. M. Vitamin K1 intake is associated with higher bone mineral density and reduced bone resorption in early postmenopausal Scottish women: no evidence of gene-nutrient interaction with apolipoprotein E polymorphisms. Am.J.Clin.Nutr. 2008;87(5):1513-1520. View abstract.
  • Makris, M., Greaves, M., Phillips, W. S., Kitchen, S., Rosendaal, F. R., and Preston, E. F. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb.Haemost. 1997;77(3):477-480. View abstract.
  • Malik, S., Udani, R. H., Bichile, S. K., Agrawal, R. M., Bahrainwala, A. T., and Tilaye, S. Comparative study of oral versus injectable vitamin K in neonates. Indian Pediatr. 1992;29(7):857-859. View abstract.
  • Marti-Carvajal, A. J., Cortes-Jofre, M., and Marti-Pena, A. J. Vitamin K for upper gastrointestinal bleeding in patients with liver diseases. Cochrane.Database.Syst.Rev. 2008;(3):CD004792. View abstract.
  • Maurage, C., Dalloul, C., Moussa, F., Cara, B., Dudragne, D., Lion, N., and Amedee-Manesme, O. [Efficacy of oral administration of a micellaar solution of vitamin K during the neonatal period]. Arch.Pediatr. 1995;2(4):328-332. View abstract.
  • Morales, W. J., Angel, J. L., O'Brien, W. F., Knuppel, R. A., and Marsalisi, F. The use of antenatal vitamin K in the prevention of early neonatal intraventricular hemorrhage. Am.J.Obstet.Gynecol. 1988;159(3):774-779. View abstract.
  • Motohara, K., Endo, F., and Matsuda, I. Effect of vitamin K administration on acarboxy prothrombin (PIVKA-II) levels in newborns. Lancet 8-3-1985;2(8449):242-244. View abstract.
  • Motohara, K., Endo, F., and Matsuda, I. Vitamin K deficiency in breast-fed infants at one month of age. J.Pediatr.Gastroenterol.Nutr. 1986;5(6):931-933. View abstract.
  • Napolitano, M., Mariani, G., and Lapecorella, M. Hereditary combined deficiency of the vitamin K-dependent clotting factors. Orphanet.J.Rare.Dis. 2010;5:21. View abstract.
  • Nee, R., Doppenschmidt, D., Donovan, D. J., and Andrews, T. C. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am.J.Cardiol. 1-15-1999;83(2):286-287. View abstract.
  • Nimptsch, K., Rohrmann, S., and Linseisen, J. Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). Am.J.Clin.Nutr. 2008;87(4):985-992. View abstract.
  • Nimptsch, K., Rohrmann, S., Kaaks, R., and Linseisen, J. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). Am.J.Clin.Nutr. 2010;91(5):1348-1358. View abstract.
  • Nishiguchi, S., Shimoi, S., Kurooka, H., Tamori, A., Habu, D., Takeda, T., and Kubo, S. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. J.Hepatol. 2001;35(4):543-545. View abstract.
  • Novotny, J. A., Kurilich, A. C., Britz, S. J., Baer, D. J., and Clevidence, B. A. Vitamin K absorption and kinetics in human subjects after consumption of 13C-labelled phylloquinone from kale. Br.J.Nutr. 2010;104(6):858-862. View abstract.
  • O'Connor, M. E. and Addiego, J. E., Jr. Use of oral vitamin K1 to prevent hemorrhagic disease of the newborn infant. J.Pediatr. 1986;108(4):616-619. View abstract.
  • Olson, R. E., Chao, J., Graham, D., Bates, M. W., and Lewis, J. H. Total body phylloquinone and its turnover in human subjects at two levels of vitamin K intake. Br.J.Nutr. 2002;87(6):543-553. View abstract.
  • Patel, R. J., Witt, D. M., Saseen, J. J., Tillman, D. J., and Wilkinson, D. S. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000;20(10):1159-1166. View abstract.
  • Pathak A, Hamm CR, Eyal FG, Walter K, Rijhsinghani A, and Bohlman M. Maternal vitamin K administration for prevention of intraventricular hemorrhage in preterm infants. Pediatric Research 1990;27:219A.
  • Pendry, K., Bhavnani, M., and Shwe, K. The use of oral vitamin K for reversal of over-warfarinization. Br.J.Haematol. 2001;113(3):839-840. View abstract.
  • Pengo, V., Banzato, A., Garelli, E., Zasso, A., and Biasiolo, A. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul.Fibrinolysis 1993;4(5):739-741. View abstract.
  • Penning-van Beest, F. J., Rosendaal, F. R., Grobbee, D. E., van, Meegen E., and Stricker, B. H. Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br.J.Haematol. 1999;104(2):241-245. View abstract.
  • Poli, D., Antonucci, E., Lombardi, A., Gensini, G. F., Abbate, R., and Prisco, D. Safety and effectiveness of low dose oral vitamin K1 administration in asymptomatic out-patients on warfarin or acenocoumarol with excessive anticoagulation. Haematologica 2003;88(2):237-238. View abstract.
  • Pomerance, J. J., Teal, J. G., Gogolok, J. F., Brown, S., and Stewart, M. E. Maternally administered antenatal vitamin K1: effect on neonatal prothrombin activity, partial thromboplastin time, and intraventricular hemorrhage. Obstet.Gynecol. 1987;70(2):235-241. View abstract.
  • Preston, F. E., Laidlaw, S. T., Sampson, B., and Kitchen, S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br.J.Haematol. 2002;116(3):619-624. View abstract.
  • Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. J.Hepatol. 1989;9(1):75-83. View abstract.
  • Puckett, R. M. and Offringa, M. Prophylactic vitamin K for vitamin K deficiency bleeding in neonates. Cochrane.Database.Syst.Rev. 2000;(4):CD002776. View abstract.
  • Raj, G., Kumar, R., and McKinney, W. P. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch.Intern.Med. 12-13-1999;159(22):2721-2724. View abstract.
  • Rashid, M., Durie, P., Andrew, M., Kalnins, D., Shin, J., Corey, M., Tullis, E., and Pencharz, P. B. Prevalence of vitamin K deficiency in cystic fibrosis. Am.J.Clin.Nutr. 1999;70(3):378-382. View abstract.
  • Rees, K., Guraewal, S., Wong, Y. L., Majanbu, D. L., Mavrodaris, A., Stranges, S., Kandala, N. B., Clarke, A., and Franco, O. H. Is vitamin K consumption associated with cardio-metabolic disorders? A systematic review. Maturitas 2010;67(2):121-128. View abstract.
  • Riegert-Johnson, D. L. and Volcheck, G. W. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann.Allergy Asthma Immunol. 2002;89(4):400-406. View abstract.
  • Sasaki, N., Kusano, E., Takahashi, H., Ando, Y., Yano, K., Tsuda, E., and Asano, Y. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J.Bone Miner.Metab 2005;23(1):41-47. View abstract.
  • Sato, Y., Honda, Y., Hayashida, N., Iwamoto, J., Kanoko, T., and Satoh, K. Vitamin K deficiency and osteopenia in elderly women with Alzheimer's disease. Arch.Phys.Med.Rehabil. 2005;86(3):576-581. View abstract.
  • Sato, Y., Honda, Y., Kaji, M., Asoh, T., Hosokawa, K., Kondo, I., and Satoh, K. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone 2002;31(1):114-118. View abstract.
  • Sato, Y., Honda, Y., Kuno, H., and Oizumi, K. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 1998;23(3):291-296. View abstract.
  • Sato, Y., Kaji, M., Tsuru, T., Satoh, K., and Kondo, I. Vitamin K deficiency and osteopenia in vitamin D-deficient elderly women with Parkinson's disease. Arch.Phys.Med.Rehabil. 2002;83(1):86-91. View abstract.
  • Sato, Y., Kanoko, T., Satoh, K., and Iwamoto, J. Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease. Bone 2005;36(1):61-68. View abstract.
  • Sato, Y., Tsuru, T., Oizumi, K., and Kaji, M. Vitamin K deficiency and osteopenia in disuse-affected limbs of vitamin D-deficient elderly stroke patients. Am.J.Phys.Med.Rehabil. 1999;78(4):317-322. View abstract.
  • Sharma, R. K., Marwaha, N., Kumar, P., and Narang, A. Effect of oral water soluble vitamin K on PIVKA-II levels in newborns. Indian Pediatr. 1995;32(8):863-867. View abstract.
  • Shea, M. K., Booth, S. L., Gundberg, C. M., Peterson, J. W., Waddell, C., Dawson-Hughes, B., and Saltzman, E. Adulthood obesity is positively associated with adipose tissue concentrations of vitamin K and inversely associated with circulating indicators of vitamin K status in men and women. J.Nutr. 2010;140(5):1029-1034. View abstract.
  • Shea, M. K., O'Donnell, C. J., Hoffmann, U., Dallal, G. E., Dawson-Hughes, B., Ordovas, J. M., Price, P. A., Williamson, M. K., and Booth, S. L. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am.J.Clin.Nutr. 2009;89(6):1799-1807. View abstract.
  • Shetty, H. G., Backhouse, G., Bentley, D. P., and Routledge, P. A. Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1. Thromb.Haemost. 1-23-1992;67(1):13-15. View abstract.
  • Shiraki M. Vitamin K2 effects on the risk of fractures and on lumbar bone mineral density in osteoporosis - a randomized prospective open-label 3-year study. Osteoporos Int 2002;13:S160.
  • Somekawa, Y., Chigughi, M., Harada, M., and Ishibashi, T. Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. J.Clin.Endocrinol.Metab 1999;84(8):2700-2704. View abstract.
  • Sorensen, B., Johansen, P., Nielsen, G. L., Sorensen, J. C., and Ingerslev, J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul.Fibrinolysis 2003;14(5):469-477. View abstract.
  • Stevenson, M., Lloyd-Jones, M., and Papaioannou, D. Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol.Assess. 2009;13(45):iii-134. View abstract.
  • Summaries for patients. Is vitamin K helpful for people who have taken too much warfarin? Ann.Intern.Med. 3-3-2009;150(5):I25. View abstract.
  • Sutherland, J. M., Glueck, H. I., and Gleser, G. Hemorrhagic disease of the newborn. Breast feeding as a necessary factor in the pathogenesis. Am.J.Dis.Child 1967;113(5):524-533. View abstract.
  • Chrubasik S, Model A, Black A, and et al. A randomized double-blind pilot study comparing Doloteffin&reg; and Vioxx&reg; in the treatment of low back pain. Rheumatology 2003;42:141-148.
  • Chrubasik S, Sporer F, Dillmann-Marschner R, et al. Physicochemical properties of harpagoside and its in vitro release from Harpagophytum procumbens extract tablets. Phytomedicine 2000;6:469-73. View abstract.
  • Chrubasik S, Thanner J, Kunzel O, et al. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip. Phytomedicine 2002;9:181-94. View abstract.
  • Circosta C, Occhiuto F, Ragusa S, et al. A drug used in traditional medicine: Harpagophytum procumbens DC. II. Cardiovascular activity. J Ethnopharmacol 1984;11:259-74. View abstract.
  • Conrozier T, Mathieu P, Bonjean M, et al. A complex of three natural anti-inflammatory agents provides relief of osteoarthritis pain. Altern Ther Health Med. 2014;20 Suppl 1:32-7.View abstract.
  • Costa De Pasquale R, Busa G, et al. A drug used in traditional medicine: Harpagophytum procumbens DC. III. Effects on hyperkinetic ventricular arrhythmias by reperfusion. J Ethnopharmacol 1985;13:193-9 . View abstract.
  • Cuspidi C, Sala C, Tadic M, et al. Systemic hypertension induced by Harpagophytum procumbens (devil's claw): a case report. J Clin Hypertens (Greenwich) 2015;17(11):908-10. View abstract.
  • Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999.
  • Fiebich BL, Heinrich M, Hiller KO, Kammerer N. Inhibition of TNF-alpha synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicine 2001;8:28-30.. View abstract.
  • Gagnier JJ, Chrubasik S, Manheimer E. Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med 2004;4:13. View abstract.
  • Gagnier JJ, van Tulder MW, Berman B, Bombardier C. Herbal medicine for low back pain. A Cochrane review. Spine 2007;32:82-92. View abstract.
  • Grahame R, Robinson BV. Devils's claw (Harpagophytum procumbens): pharmacological and clinical studies. Ann Rheum Dis 1981;40:632. View abstract.
  • Jang MH, Lim S, Han SM, et al. Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929. J Pharmacol Sci 2003;93:367-71. View abstract.
  • Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995;346:270-4. View abstract.
  • Lanhers MC, Fleurentin J, Mortier F, et al. Anti-inflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens. Planta Med 1992;58:117-23 . View abstract.
  • Mahomed IM, Ojewole JAO. Oxytocin-like effect of Harpagophytum procumbens [Pedaliacae] secondary root aqueous extract on rat isolated uterus. Afr J Trad CAM 2006;3(1):82-89.
  • Moussard C, Alber D, Toubin MM, et al. A drug used in traditional medicine, harpagophytum procumbens: no evidence for NSAID-like effect on whole blood eicosanoid production in human. Prostaglandins Leukot Essent Fatty Acids. 1992;46:283-6.. View abstract.
  • Romiti N, Tramonti G, Corti A, Chieli E. Effects of Devil's Claw (Harpagophytum procumbens) on the multidrug transporter ABCB1/P-glycoprotein. Phytomedicine 2009;16:1095-100. View abstract.
  • Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). Drug Saf 1997;17:342-56. View abstract.
  • Soulimani R, Younos C, Mortier F, Derrieu C. The role of stomachal digestion on the pharmacological activity of plant extracts, using as an example extracts of Harpagophytum procumbens. Can J Physiol Pharmacol 1994;72:1532-6. View abstract.
  • Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;18:2273-81. View abstract.
  • Wegener T, Lupke NP. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC). Phytother Res 2003;17:1165-72. View abstract.
  • Whitehouse LW, Znamirowska M, Paul CJ. Devil's Claw (Harpagophytum procumbens): no evidence for anti-inflammatory activity in the treatment of arthritic disease. Can Med Assoc J 1983;129:249-51. View abstract.

Vitamins Survey

Have you ever purchased DEVIL'S CLAW?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

More Resources for DEVIL'S CLAW

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.